The Role of Liquid Biopsy in Metastatic Prostate Cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.24915/aup.37.1-2.116 |
Resumo: | Prostate cancer is the second most common malignancy in men. The high prevalence of prostate cancer, as well as its relatively indolent clinical course and the emerging therapeutic options, have led to the need to identify biomarkers that may aid in clinical decisions and may reflect response to treatments. “Liquid biopsy” is a generic term applied to the study of biomarkers attributed to tumors that are circulating in the body fluids of cancer patients. It relies on the principle that in these patients there are tumor cells and fragments with genomic content of tumor that circulate and can be detected and used as biomarkers for clinical application. Most of these biomarkers correlate with tumor burden and are most often identified in individuals with metastatic disease. The most studied biomarkers in prostate cancer patients can be subdivided into three major groups: circulating tumor cells, free genetic material (such as RNA and DNA - namely, microRNA and circulating free DNA) and extracellular vesicles (where there is inclusion of specific material and single tumor). This knowledge may allow the development of potential clinical applications from diagnosis to prognosis, as well as the development of predictive biomarkers of response to treatment and disease monitoring. |
id |
RCAP_40de76a8a029cec3c63e59e5998e75b5 |
---|---|
oai_identifier_str |
oai:oai.actaurologicaportuguesa.com:article/116 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The Role of Liquid Biopsy in Metastatic Prostate CancerO Papel da Biópsia Líquida no Cancro da Próstata MetastizadoBiomarkers, TumorLiquid BiopsyProstatic NeoplasmsBiomarcadores TumoraisBiópsia LíquidaNeoplasias da ProstataProstate cancer is the second most common malignancy in men. The high prevalence of prostate cancer, as well as its relatively indolent clinical course and the emerging therapeutic options, have led to the need to identify biomarkers that may aid in clinical decisions and may reflect response to treatments. “Liquid biopsy” is a generic term applied to the study of biomarkers attributed to tumors that are circulating in the body fluids of cancer patients. It relies on the principle that in these patients there are tumor cells and fragments with genomic content of tumor that circulate and can be detected and used as biomarkers for clinical application. Most of these biomarkers correlate with tumor burden and are most often identified in individuals with metastatic disease. The most studied biomarkers in prostate cancer patients can be subdivided into three major groups: circulating tumor cells, free genetic material (such as RNA and DNA - namely, microRNA and circulating free DNA) and extracellular vesicles (where there is inclusion of specific material and single tumor). This knowledge may allow the development of potential clinical applications from diagnosis to prognosis, as well as the development of predictive biomarkers of response to treatment and disease monitoring.O cancro da próstata é a segunda neoplasia maligna mais frequente nos homens em todo o mundo. A elevada prevalência do cancro da próstata, bem como o seu curso clínico relativamente indolente e as opções terapêuticas emergentes, conduziram à necessidade de identificação de biomarcadores que possam auxiliar nas decisões clínicas e refletir a resposta aos tratamentos. Na era da medicina de precisão, para uma correta decisão terapêutica é mandatória a caracterização individual de cada tumor. “Biópsia líquida” é um termo genérico aplicado ao estudo de biomarcadores atribuídos aos tumores que se encontram em circulação nos fluídos corporais de doentes com cancro. Baseia- -se no princípio de que nestes doentes existem células tumorais e fragmentos com conteúdo genómico de células tumorais que entram em circulação, podendo ser detetados e usados como biomarcadores para aplicação clínica. A maioria destes biomarcadores correlaciona-se com a carga tumoral, sendo mais frequentemente identificados em indivíduos com doença disseminada. Os biomarcadores mais estudados em doentes com cancro da próstata podem ser subdivididos em três grandes grupos: células tumorais circulantes (CTCs), material genético livre (como RNA e DNA - designadamente, microRNA (miRNA) e DNA livre circulante (cfDNA), incluindo o cfDNA total do doente e o DNA específico do tumor (cftDNA)) e micro vesículas extracelulares (onde há inclusão de material específico e único do tumor). Este conhecimento pode permitir desenvolver potenciais aplicações clínicas desde o diagnóstico ao prognóstico, bem como o desenvolvimento de biomarcadores preditivos de resposta aos tratamentos e de monitorização da doença.Associação Portuguesa de Urologia2020-07-17T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.24915/aup.37.1-2.116oai:oai.actaurologicaportuguesa.com:article/116Acta Urológica Portuguesa; Vol. 36 No. 3-4 (2019): July-September; October-December; 91-102Acta Urológica Portuguesa; v. 36 n. 3-4 (2019): Julho-Setembro; Outubro-Dezembro; 91-1022387-04192341-4022reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://www.actaurologicaportuguesa.com/index.php/aup/article/view/116https://doi.org/10.24915/aup.37.1-2.116http://www.actaurologicaportuguesa.com/index.php/aup/article/view/116/58Copyright (c) 2020 Portuguese Association of Urologyhttp://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessGlória, JoanaNunes-Carneiro, DiogoFraga, Avelino2022-09-21T09:04:48Zoai:oai.actaurologicaportuguesa.com:article/116Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:55:54.883179Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The Role of Liquid Biopsy in Metastatic Prostate Cancer O Papel da Biópsia Líquida no Cancro da Próstata Metastizado |
title |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
spellingShingle |
The Role of Liquid Biopsy in Metastatic Prostate Cancer Glória, Joana Biomarkers, Tumor Liquid Biopsy Prostatic Neoplasms Biomarcadores Tumorais Biópsia Líquida Neoplasias da Prostata |
title_short |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
title_full |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
title_fullStr |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
title_full_unstemmed |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
title_sort |
The Role of Liquid Biopsy in Metastatic Prostate Cancer |
author |
Glória, Joana |
author_facet |
Glória, Joana Nunes-Carneiro, Diogo Fraga, Avelino |
author_role |
author |
author2 |
Nunes-Carneiro, Diogo Fraga, Avelino |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Glória, Joana Nunes-Carneiro, Diogo Fraga, Avelino |
dc.subject.por.fl_str_mv |
Biomarkers, Tumor Liquid Biopsy Prostatic Neoplasms Biomarcadores Tumorais Biópsia Líquida Neoplasias da Prostata |
topic |
Biomarkers, Tumor Liquid Biopsy Prostatic Neoplasms Biomarcadores Tumorais Biópsia Líquida Neoplasias da Prostata |
description |
Prostate cancer is the second most common malignancy in men. The high prevalence of prostate cancer, as well as its relatively indolent clinical course and the emerging therapeutic options, have led to the need to identify biomarkers that may aid in clinical decisions and may reflect response to treatments. “Liquid biopsy” is a generic term applied to the study of biomarkers attributed to tumors that are circulating in the body fluids of cancer patients. It relies on the principle that in these patients there are tumor cells and fragments with genomic content of tumor that circulate and can be detected and used as biomarkers for clinical application. Most of these biomarkers correlate with tumor burden and are most often identified in individuals with metastatic disease. The most studied biomarkers in prostate cancer patients can be subdivided into three major groups: circulating tumor cells, free genetic material (such as RNA and DNA - namely, microRNA and circulating free DNA) and extracellular vesicles (where there is inclusion of specific material and single tumor). This knowledge may allow the development of potential clinical applications from diagnosis to prognosis, as well as the development of predictive biomarkers of response to treatment and disease monitoring. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-07-17T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.24915/aup.37.1-2.116 oai:oai.actaurologicaportuguesa.com:article/116 |
url |
https://doi.org/10.24915/aup.37.1-2.116 |
identifier_str_mv |
oai:oai.actaurologicaportuguesa.com:article/116 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
http://www.actaurologicaportuguesa.com/index.php/aup/article/view/116 https://doi.org/10.24915/aup.37.1-2.116 http://www.actaurologicaportuguesa.com/index.php/aup/article/view/116/58 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2020 Portuguese Association of Urology http://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2020 Portuguese Association of Urology http://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Associação Portuguesa de Urologia |
publisher.none.fl_str_mv |
Associação Portuguesa de Urologia |
dc.source.none.fl_str_mv |
Acta Urológica Portuguesa; Vol. 36 No. 3-4 (2019): July-September; October-December; 91-102 Acta Urológica Portuguesa; v. 36 n. 3-4 (2019): Julho-Setembro; Outubro-Dezembro; 91-102 2387-0419 2341-4022 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130427747729408 |